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ABSTRACT 
Introduction  Patients with levodopa therapy frequently require additional 
antipsychotic pharmacotherapy. However, consideration must be given to antagonistic 
interactions on dopamine receptors between levodopa and antipsychotics, and efficacy 
and safety of such combinations. We therefore aimed to explore the practice and 
rationale of coprescription between levodopa and antipsychotics in psychiatric 
patients. 
Methods  Descriptive retrospective study based on cross-sectional prescription data 
repeatedly collected from psychiatric inpatients through the international Drug Safety 
in Psychiatry (AMSP) program between 1994 and 2008. 
Results  Within a population of 84,596 psychiatric patients the prevalence of 
levodopa therapy was 1.0% (n=886). Among those patients with levodopa therapy 
59.6% (n=528) also received antipsychotics. Quetiapine coprescription increased after 
its first marketing in 2000 to 45.9% in 2008. Coprescription of clozapine and 
olanzapine decreased from up to 25 and 22%, respectively, before to less than 10% 
after introduction of quetiapine. Coprescribing of other antipsychotics remained 
approximately stable with average prevalences between 6 and less than 1%. 
Discussion  Quetiapine has now replaced clozapine as the most frequently 
coprescribed neuroleptic in psychiatric patients with levodopa therapy. This is in 
accordance with recent data indicating a low potential for clincially relevant 
interactions with levodopa and efficacy against psychosis in levodopa-treated patients. 
The combined use of other antipsychotics than quetiapine and clozapine with 
levodopa is less common and generally not supported by appropriate evidence. 
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INTRODUCTION 
Levodopa is indicated for the treatment of idiopathic Parkinson’s disease (PD), 
Parkinson syndromes, and restless legs syndrome (RLS), but not for drug-induced 
extrapyramidal symptoms (EPS). PD is associated with psychosis with an estimated 
incidence rate of 79.7 per 1000 person-years [1], and central dopaminergic 
overactivity as well as an imbalance in the cholinergic neurotransmission play a key 
role in the underlying pathophysiology  [2, 3]. On the one hand PD itself is associated 
with psychosis [4]. But more importantly, in the majority of PD patients psychosis is 
actually precipitated by dopaminergic treatment for PD, including levodopa [1, 5, 6]. 
Similarly, the dopamine system is also involved in the pathophysiology of RLS [7], 
which is the foundation for its treatment with dopaminergic drugs including levodopa. 
In analogy to PD dopaminergic treatment for RLS is also associated with psychotic 
disorders [8]. Therefore, in order to control psychotic symptoms in levodopa-treated 
patients neurologists and psychiatrists frequently combine levodopa with 
antipsychotics in clinical practice. 
In a previous study we investigated the prevalences of interacting drug combinations 
in a large population of psychiatric inpatients collected through the international Drug 
Safety in Psychiatry (AMSP) program, but our analyses did not yet include detailed 
studies of drug interactions between selected drug classes of interest [9]. The current 
study aimed to explore the combined use of levodopa and antipsychotics in a large 
representative psychiatric inpatient population that reflects prescribing behavior in 
clinical practice over time. 
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METHODS 
 
Data Source 
AMSP is an ongoing international multicenter drug safety program that has been 
collecting data on pharmacotherapy and adverse drug events from psychiatric 
hospitals in a naturalistic setting since 1993. Its methods have been described in detail 
elsewhere [10, 11]. Briefly, AMSP consists of two principle data collections from 
more than 80 hospitals in Germany, Switzerland and Austria, and more recently also 
from one hospital each in Belgium and Hungary. First, in a cross-sectional approach 
all participating hospitals survey psychiatric inpatients on two reference days per year. 
All drugs administered on these days are recorded along with the patients’ age, gender 
and leading psychiatric diagnoses. Second, severe adverse drug events that occur at 
these hospitals during psychopharmacological drug treatment are continuously 
reported and collected. For the current study we used only the cross-sectional AMSP 
prescription dataset. 
 
Study population and design 
Selection of the study population and data management have been described in detail 
in our previous study [9]. Briefly, we received an anonymized dataset that had been 
extracted from the AMSP database and contained all cross-sectional data collected 
from the AMSP program between 1994 and 2008. Subsequently we executed 
extensive reformatting, quality controls and matching of ATC codes to all prescribed 
active substances. Compared to our previous study another 11 patients were excluded 
for the current analysis because the date of data collection was not specified, and this 
would have interfered with time trend analyses. Within the resulting population of 
84,567 patients we identified all patients with prescriptions for levodopa and recorded 
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all concomitant prescriptions at the day of  prescription data collection. The ethics 
committee of the Ludwig Maximilian University Munich, the location of the AMSP 
main data center, had approved the study with a waiver of authorization. 
 
Data analysis 
Data analysis was primarily descriptive with presentation of results in tables and 
graphs as appropriate. The chi-square test was used for comparing changes in the 
proportion of patients with prescriptions of specific drugs over two different time 
strata. Alternatively, we fitted changes over several calendar years to a simple linear 
regression model. Data management, analyses, tables and graphs were done using 
STATA Version 11.2 for MacOS X (STATA Corporation, College Station, TX, USA) 
and SPSS Version 18 for MacOS X (IBM Corporation, Somers, NY, USA). 
 
RESULTS 
Characteristics and overall pharmacotherapy of patients with levodopa therapy 
Among 84,567 psychiatric inpatients we identified 886 patients with a prescription of 
levodopa. Looking at time trends for levodopa use in the source population we found 
that the proportion of patients with levodopa prescriptions increased by 29% from 
0.9% to 1.2% (p<0.005) comparing the time strata from 1994-2002 vs. 2003-2008, 
and we also noticed a trend towards a continuous increase over time by calendar years 
(linear regression: R2=0.49, p=0.004). This increase may at least partially be 
attributable to an increasing number of gerontopsychiatric wards that contributed to 
data collection in the source population over time. Characteristics of patients with 
levodopa treatment are presented in Table 1. Of note, available ICD-10 diagnoses are 
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primary psychiatric admission diagnoses that are reliably captured in the database 
along with all prescribed drugs, whereas reliable information regarding the indication 
or dose of pharmacotherapy was not available. Most frequently coprescribed drug 
classes are presented in Table 2, showing that antipsychotics, antidepressants and 
anxiolytics are the top three coprescribed drug classes in psychiatric patients with 
levodopa therapy. Therapy with other dopaminergic drugs in addition to levodopa is 
presented in Table 3. Among all 886 patients with levodopa therapy 239 (27.0%) had 
at least one additional dopaminergic drug that is typically combined with levodopa for 
the treatment of PD or Parkinson syndrome and therefore strongly suggest those as 
the underlying indication. The remaining 647 (73.0%) patients had dopaminergic 
monotherapy with levodopa, compatible with either PD, Parkinson syndrome or 
restless legs syndrome as the most likely indication. 
Coprescribing of levodopa and antipsychotics 
Combined use of levodopa and antipsychotics is presented in Table 4 and Figure 1. 
Clozapine use showed a moderate decrease in an approximately linear fashion 
between 1996 and 2008 (linear regression analysis: R2=0.51, p=0.006). However, the 
most prominent finding is the steep increase in the concomitant prescription of 
levodopa with quetiapine after its introduction in 2000, so that in 2008 a remarkable 
45.9% of all psychiatric patients with levodopa treatment also received quetiapine. 
Comparing patients with dopaminergic levodopa monotherapy vs. those with at least 
one more dopaminergic drug and therefore a likely underyling diagnosis of PD or 
Parkinson syndrome, the latter group had a moderately higher proportion of 
concomitant quetiapine use (25.5% vs. 18.7%, p=0.03), whereas the overall use of 
antipsychotics was similar (59.0% vs. 59.8%, p>0.05). We also found a noticeable 
temporal relationship between the introduction of quetiapine and the reduced use of 
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olanzapine plus levodopa that occurred from 2002 onwards. The combined use of 
other antipsychotics with levodopa did not show obvious time trends and was lower, 
with an average prevalence between 0.1 and 5.9% (see Table 4). Furthermore, we also 
identified seven patients where levodopa was combined with the formally 
contraindicated antidopaminergic drug metoclopramide. 
 
DISCUSSION 
Coprescription of antipsychotics has a high prevalence in psychiatric patients treated 
with levodopa, but counteracting pharmacodynamic effects on the dopamine system 
may represent a therapeutic challenge, independent of the underlying indication for 
levodopa. This observational study analyzed the long-term changes in prescribing 
behavior of combined use of levodopa and antipsychotics in a representative natural 
psychiatric inpatient setting. 
Current strategies in order to control psychosis in the presence of PD and RLS include 
either a reduction or change of dopaminergic treatment because it can exacerbate 
hallucinations and other psychotic symptoms [2]. If psychotic symptoms persist even 
with the lowest levodopa dose that allows adequate control of motor symptoms 
additional treatment with antipsychotics is warranted. However, levodopa and most 
antipsychotics have antagonistic effects on the dopamine system, which may 
compromise levodopa’s desired effects on motor function. Therefore antipsychotics 
with a low potential to induce EPS are required, and for a long time clozapine was the 
neuroleptic that met this requirement best [12]. 
Accordingly our results show that up to the introduction of olanzapine in 1997 
clozapine was the most commonly coprescribed neuroleptic with levodopa. Clozapine 
has a regional selectivity for dopamine receptors in the mesolimbic „behavioral“ 
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system, rather than the nigrostriatal „motor“ system, and over 80% of patients with 
PD respond to clozapine with complete or partial resolution of psychosis [12, 13]. 
Despite clozapine’s efficacy even at very low doses for this indication, adverse effects 
such as sedation, hypersalivation, orthostatic hypotension, and agranulocytosis are 
important limiting factors for its use, and the latter mandates frequent blood testing in 
patients treated with clozapine. In addition, several reports of fatal myocarditis in 
patients treated with clozapine were published between 1995 and 2000 [14-16]. Those 
reports and the introduction of alternative atypical antipsychotics coincide with the 
decreased concomitant use of clozapine with levodopa that we observed in our study, 
particularly after the introduction of olanzapine. Our data show that the combined 
prescription of olanzapine with levodopa first rapidly increased, but then equally 
rapidly decreased after the introduction of quetiapine. Although initial open-label 
studies of olanzapine showed beneficial effects [17, 18], later controlled trials showed 
no clear benefit and worsening of motor function, which argue against combined use 
of olanzapine with levodopa [19, 20]. 
In contrast, the combined use of levodopa with quetiapine is supported by several 
studies. Although two double-blind placebo-controlled studies failed to show 
beneficial effects of quetiapine on psychotic symptoms in PD [21, 22], an open-label 
as well as a recent well-designed double-blind controlled study between clozapine and 
quetiapine support the efficacy of quetiapine for the treatment of psychosis in PD [23, 
24]. Indeed, based on our finding that in 2008 every other psychiatric patient with 
levodopa also received quetiapine, clinical prescribing practice also appears to be in 
accordance with a favorable efficacy and safety profile. Furthermore, a beneficial 
sleep-promoting effect has also been reported for quetiapine [2]. 
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Melperone may be another alternative according to one uncontrolled study [25], 
which may explain the occasional combined use with levodopa in our data, but there 
are no controlled studies that support its use in the treatment of psychosis in PD. 
Other atypical antipsychotics are not commonly combined with levodopa according to 
our findings. Indeed, although drugs such as risperidone, aripiprazole or ziprasidone 
are generally considered to have a low risk to induce EPS, a worsening of motor 
function has been observed, particularly in the treatment of psychosis in PD patients, 
and their combined use with levodopa can therefore not be recommended [26-30]. 
Limitations of our descriptive study include particularly a lack of information on drug 
doses and clinical outcomes. The risk of levodopa-associated psychosis is dose-
dependent [1], and patients with PD may receive daily doses of up to 1500 mg, 
whereas daily doses in RLS usully do not exceed 250 mg. This may also be a possible 
explanation for the observed higher proportion of  concomitant quetiapine use in 
patients with several dopaminergic drugs. These patients may have a high risk of 
drug-induced psychosis on the one hand, but a high need to control motor symptoms 
without interference by antipsychotic treatment on the on the other hand. 
Antipsychotics are therefore typically started with very low doses in this situation, 
e.g. only 25 mg per day for quetiapine. Furthermore, although beyond the scope of 
our study’s mainly descriptive aims and conclusions that focus on drug utilization 
over time, reliable information on the indication for levodopa and also antipsychotic 
drug use including quetiapine would have been of interest. Nevertheless, our findings 
provide important and valid information on the prevalence of levodopa use and its 
combination with antipsychotics in a very large psychiatric inpatient population. 
These data reflect the transfer of data from clinical trials and guidelines into daily 
prescribing behavior, and sometimes the experiences of prescribing physicians who 
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evaluate risks and benefits of pharmacotherapy in clinical practice may even 
anticipate recommendations based on controlled clinical trials.  
 
In conclusion, quetiapine has now replaced clozapine as the most frequently 
coprescribed neuroleptic in psychiatric patients with levodopa therapy in clinical 
practice. This observation is in line with recent data from controlled studies that 
showed an overall favorable efficacy and safety profile of quetiapine in combination 
with levodopa. Clozapine use is supported by its well documented efficacy, but 
adverse effects, mainly bone marrow toxicity, are an important limiting factor for its 
use. Other antipsychotics than quetiapine and clozapine are less frequently combined 
with levodopa and with questionable rationale. Their use is generally not supported by 
appropriate evidence and should be discouraged unless exceptionally justifiable in 
individual patients. 
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TABLES 
 
Tables 
 
Table 1  - Characteristics of patients with levodopa therapy (N = 886). 
 
Characteristics Frequency 
  
Age in years, median (range) 72 (12 -  95) 
Gender, n (%)  
Female 515 (58.1) 
Male 371 (41.9) 
Primary ICD-10 diagnoses, n (%)  
Mental and behavioral disorders 838 (94.6) 
Mood affective disorders 323 (36.5) 
Organic psychoses 318 (35.9) 
Schizophrenia 94 (10.6) 
Neuroses 47 (5.3) 
Psychoactive substance abuse 35 (4.0) 
Personality and behavioral disorders 21 (2.4) 
Unspecified 25 (2.8) 
Other non-psychiatric diagnoses 23 (2.6) 
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Table 2  - Most frequent coprescribed drug classes in patients with levodopa 
therapy 
 n  % 
   
Levodopa  886 100 
   
Coprescribed drug classes   
Antipsychotics 528 59.6 
Antidepressants 526 59.4 
Anxiolytics, sedatives and hypnotics 347 39.2 
NSAIDs 222 25.1 
Diuretics 219 24.7 
Drugs for peptic ulcer 219 24.7 
Renin-angiotensin-aldosterone system inhibitors 183 20.7 
Anticonvulsants 178 20.1 
Laxatives 169 19.1 
Beta-blocking agents 143 16.1 
Other hormones 138 15.6 
Antithrombotics 129 14.6 
Mineral supplements 128 14.4 
Anti-dementia agents 106 12.0 
Antianemic agents 94 10.6 
Vitamins 76 8.6 
Calcium channel blockers 75 8.5 
Cardiac stimulants and antiarrhythmics 66 7.4 
Antidiabetic agents 65 7.3 
 
  3 
Table 3  - Coprescription of other dopaminergic drugs with levodopa 
 n % 
   
Levodopa 886 100 
   
Coprescribed other dopaminergic drugs   
At least one dopaminergic drug listed below 239 27.0 
   
Amantadin 64 7.2 
Pramipexol 44 5.0 
Selegilin 36 4.1 
Entacapon 36 4.1 
Cabergolin 29 3.3 
Ropinirol 24 2.7 
Pergolid 21 2.4 
Bromocriptin 14 1.6 
Dihydroergocriptin 12 1.4 
Lisurid 9 1.0 
Tolcapon 2 0.2 
Apomorphin 1 0.1 
Rotigotin 1 0.1 
Quinagolid 0 0 
Rasagilin 0 0 
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Table 4  - Coprescription of antipsychotics with levodopa including time trends 
 Overall frequency Time trends 
 
 
 
n 
 
 
% 
1994-2002 
(n=328) 
% 
2003-2008 
(n=558) 
% 
 
 
p-value1 
      
Levodopa 886 100 100 100 - 
      
Coprescribed antipsychotics      
Atypical      
Quetiapine 182 20.5 4.9 29.7 <0.001 
Clozapine 87 9.8 11.9 8.6 0.112 
Olanzapine 73 8.2 12.8 5.6 <0.001 
Risperidone 34 3.8 3.7 3.9 0.83 
Amisulpride 14 1.6 0.6 2.2 0.08 
Aripiprazole 3 0.3 0.5 0 0.18 
Zotepine 3 0.3 0.6 0.2 0.29 
Sulpiride 2 0.2 0 0.4 0.28 
Sertindole 1 0.1 0 0.2 0.44 
Ziprasidone 1 0.1 0 0.2 0.44 
      
Conventional      
Melperone 52 5.9 6.4 5.6 0.60 
Pipamperone 46 5.2 4.6 5.6 0.52 
Chlorprothixene 24 2.7 2.1 3.0 0.42 
Prothipendyle 23 2.6 2.1 2.9 0.51 
Haloperidol 19 2.1 1.8 2.3 0.62 
Levomepromazin 14 1.6 2.4 1.1 0.12 
Flupentixole 9 1.0 0 1.6 0.02 
Perazine 7 0.8 1.8 0.2 0.007 
      
Metoclopramide 7 0.8 0.9 0.7 0.75 
 
1 chi-square test comparing time strata 1994-2002 vs. 2003-2008 
2 1994-1999 (before introduction of quetiapine) vs. 2000-2008: 17.5% vs. 8.1%, p<0.001 
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Figure 1
